

Tildrakizumab

Cat. No.:	HY-P99256
CAS No.:	1326244-10-3
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (K_d : 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis ^{[1][2][3]} .
IC₅₀ & Target	IL-23 ^[1]
In Vitro	Tildrakizumab inhibits IL-23-induced STAT3 signaling in HeLa cells expressed the human IL-23R α and IL-12R β 1 receptors, with an IC ₅₀ of 23 pM ^[2] . Tildrakizumab reduces IL-23's affinity for IL-23R α through a negative allosteric modulation ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Tildrakizumab (100 mg/kg, s.c., every 2 weeks up to 9 months) is well tolerated in cynomolgus monkeys (toxicity studies) ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Papp K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. *Br J Dermatol.* 2015 Oct;173(4):930-9.
- [2]. Zhou L, et al. A non-clinical comparative study of IL-23 antibodies in psoriasis. *MAbs.* 2021 Jan-Dec;13(1):1964420.
- [3]. Santostefano M, et al. Nonclinical safety of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody, in nonhuman primates. *Regul Toxicol Pharmacol.* 2019 Nov;108:104476.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA